ROR1 and diffuse large B-cell lymphoma: The combination of KAN0441571C and venetoclax is also supported by a recent study showing that there is increased killing efficacy of ROR1-expressing diffuse large B-cell lymphoma (DLBCL) cell lines with the combination therapy compared to either drug alone20.